Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.

Machelart A, Salzano G, Li X, Demars A, Debrie AS, Menendez-Miranda M, Pancani E, Jouny S, Hoffmann E, Deboosere N, Belhaouane I, Rouanet C, Simar S, Talahari S, Giannini V, Villemagne B, Flipo M, Brosch R, Nesslany F, Deprez B, Muraille E, Locht C, Baulard AR, Willand N, Majlessi L, Gref R, Brodin P.

ACS Nano. 2019 Apr 23;13(4):3992-4007. doi: 10.1021/acsnano.8b07902. Epub 2019 Mar 8.

PMID:
30822386
2.

Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity.

Ates LS, Dippenaar A, Sayes F, Pawlik A, Bouchier C, Ma L, Warren RM, Sougakoff W, Majlessi L, van Heijst JWJ, Brossier F, Brosch R.

Genome Biol Evol. 2018 Aug 1;10(8):1858-1874. doi: 10.1093/gbe/evy145.

3.

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection.

Ates LS, Sayes F, Frigui W, Ummels R, Damen MPM, Bottai D, Behr MA, van Heijst JWJ, Bitter W, Majlessi L, Brosch R.

PLoS Pathog. 2018 Jun 18;14(6):e1007139. doi: 10.1371/journal.ppat.1007139. eCollection 2018 Jun.

4.

Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.

Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP, Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, Gref R.

Sci Rep. 2018 May 10;8(1):7596. doi: 10.1038/s41598-018-25177-2.

5.

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors.

Sayes F, Blanc C, Ates LS, Deboosere N, Orgeur M, Le Chevalier F, Gröschel MI, Frigui W, Song OR, Lo-Man R, Brossier F, Sougakoff W, Bottai D, Brodin P, Charneau P, Brosch R, Majlessi L.

Cell Rep. 2018 Apr 24;23(4):1072-1084. doi: 10.1016/j.celrep.2018.03.125.

6.

Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus.

Laencina L, Dubois V, Le Moigne V, Viljoen A, Majlessi L, Pritchard J, Bernut A, Piel L, Roux AL, Gaillard JL, Lombard B, Loew D, Rubin EJ, Brosch R, Kremer L, Herrmann JL, Girard-Misguich F.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E1002-E1011. doi: 10.1073/pnas.1713195115. Epub 2018 Jan 17.

7.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.

Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP, Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, Gref R.

Sci Rep. 2017 Jul 14;7(1):5390. doi: 10.1038/s41598-017-05453-3. Erratum in: Sci Rep. 2018 May 10;8(1):7596.

8.

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection.

Gröschel MI, Sayes F, Shin SJ, Frigui W, Pawlik A, Orgeur M, Canetti R, Honoré N, Simeone R, van der Werf TS, Bitter W, Cho SN, Majlessi L, Brosch R.

Cell Rep. 2017 Mar 14;18(11):2752-2765. doi: 10.1016/j.celrep.2017.02.057.

9.

Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis.

Majlessi L, Sayes F, Bureau JF, Pawlik A, Michel V, Jouvion G, Huerre M, Severgnini M, Consolandi C, Peano C, Brosch R, Touati E, Leclerc C.

Mucosal Immunol. 2017 Sep;10(5):1178-1189. doi: 10.1038/mi.2016.140. Epub 2017 Feb 1.

10.

The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages.

Roux AL, Viljoen A, Bah A, Simeone R, Bernut A, Laencina L, Deramaudt T, Rottman M, Gaillard JL, Majlessi L, Brosch R, Girard-Misguich F, Vergne I, de Chastellier C, Kremer L, Herrmann JL.

Open Biol. 2016 Nov;6(11). pii: 160185.

11.

A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence of Mycobacterium marinum in multiple hosts.

Singh VK, Berry L, Bernut A, Singh S, Carrère-Kremer S, Viljoen A, Alibaud L, Majlessi L, Brosch R, Chaturvedi V, Geurtsen J, Drancourt M, Kremer L.

Cell Microbiol. 2016 Nov;18(11):1489-1507. doi: 10.1111/cmi.12606. Epub 2016 Jun 1.

PMID:
27120981
12.

ESX secretion systems: mycobacterial evolution to counter host immunity.

Gröschel MI, Sayes F, Simeone R, Majlessi L, Brosch R.

Nat Rev Microbiol. 2016 Nov;14(11):677-691. doi: 10.1038/nrmicro.2016.131. Epub 2016 Sep 26. Review.

PMID:
27665717
13.

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence.

Boritsch EC, Frigui W, Cascioferro A, Malaga W, Etienne G, Laval F, Pawlik A, Le Chevalier F, Orgeur M, Ma L, Bouchier C, Stinear TP, Supply P, Majlessi L, Daffé M, Guilhot C, Brosch R.

Nat Microbiol. 2016 Jan 27;1:15019. doi: 10.1038/nmicrobiol.2015.19.

PMID:
27571976
14.

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection.

Sayes F, Pawlik A, Frigui W, Gröschel MI, Crommelynck S, Fayolle C, Cia F, Bancroft GJ, Bottai D, Leclerc C, Brosch R, Majlessi L.

PLoS Pathog. 2016 Jul 28;12(7):e1005770. doi: 10.1371/journal.ppat.1005770. eCollection 2016 Jul.

15.

Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access.

Simeone R, Majlessi L, Enninga J, Brosch R.

Cell Microbiol. 2016 Aug;18(8):1070-7. doi: 10.1111/cmi.12622. Epub 2016 Jun 29. Review.

PMID:
27247079
16.

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis.

Le Chevalier F, Cascioferro A, Frigui W, Pawlik A, Boritsch EC, Bottai D, Majlessi L, Herrmann JL, Brosch R.

Sci Rep. 2015 Nov 25;5:16918. doi: 10.1038/srep16918.

17.

Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment.

Petit-Jentreau L, Jouvion G, Charles P, Majlessi L, Gicquel B, Tailleux L.

Infect Immun. 2015 Sep;83(9):3666-74. doi: 10.1128/IAI.00418-15. Epub 2015 Jul 6.

18.

Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity.

Majlessi L, Brosch R.

Cell Host Microbe. 2015 Jun 10;17(6):733-5. doi: 10.1016/j.chom.2015.05.017.

19.

Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells.

Lemoine S, Jaron B, Tabka S, Ettreiki C, Deriaud E, Zhivaki D, Le Ray C, Launay O, Majlessi L, Tissieres P, Leclerc C, Lo-Man R.

J Allergy Clin Immunol. 2015 Nov;136(5):1355-68.e1-15. doi: 10.1016/j.jaci.2015.02.030. Epub 2015 Apr 10.

PMID:
25865351
20.

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection.

Simeone R, Bottai D, Frigui W, Majlessi L, Brosch R.

Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S150-4. doi: 10.1016/j.tube.2015.02.019. Epub 2015 Feb 13.

PMID:
25732627
21.

Release of mycobacterial antigens.

Majlessi L, Prados-Rosales R, Casadevall A, Brosch R.

Immunol Rev. 2015 Mar;264(1):25-45. doi: 10.1111/imr.12251. Review.

PMID:
25703550
22.

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.

Simeone R, Sayes F, Song O, Gröschel MI, Brodin P, Brosch R, Majlessi L.

PLoS Pathog. 2015 Feb 6;11(2):e1004650. doi: 10.1371/journal.ppat.1004650. eCollection 2015 Feb.

23.

Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development.

Le Chevalier F, Cascioferro A, Majlessi L, Herrmann JL, Brosch R.

Future Microbiol. 2014;9(8):969-85. doi: 10.2217/fmb.14.70. Review.

PMID:
25302954
24.

Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach.

Daleke-Schermerhorn MH, Felix T, Soprova Z, Ten Hagen-Jongman CM, Vikström D, Majlessi L, Beskers J, Follmann F, de Punder K, van der Wel NN, Baumgarten T, Pham TV, Piersma SR, Jiménez CR, van Ulsen P, de Gier JW, Leclerc C, Jong WS, Luirink J.

Appl Environ Microbiol. 2014 Sep;80(18):5854-65. doi: 10.1128/AEM.01941-14. Epub 2014 Jul 18.

25.

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis.

Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, Tap J, Pawlik A, Fiette L, Orgeur M, Fabre M, Parmentier C, Frigui W, Simeone R, Boritsch EC, Debrie AS, Willery E, Walker D, Quail MA, Ma L, Bouchier C, Salvignol G, Sayes F, Cascioferro A, Seemann T, Barbe V, Locht C, Gutierrez MC, Leclerc C, Bentley SD, Stinear TP, Brisse S, Médigue C, Parkhill J, Cruveiller S, Brosch R.

Nat Genet. 2013 Feb;45(2):172-9. doi: 10.1038/ng.2517. Epub 2013 Jan 6.

26.

Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells.

Dong H, Stanek O, Salvador FR, Länger U, Morillon E, Ung C, Sebo P, Leclerc C, Majlessi L.

Mucosal Immunol. 2013 May;6(3):522-34. doi: 10.1038/mi.2012.92. Epub 2012 Oct 3.

PMID:
23032790
27.

Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential.

Sayes F, Sun L, Di Luca M, Simeone R, Degaiffier N, Fiette L, Esin S, Brosch R, Bottai D, Leclerc C, Majlessi L.

Cell Host Microbe. 2012 Apr 19;11(4):352-63. doi: 10.1016/j.chom.2012.03.003.

28.

Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation.

Bottai D, Di Luca M, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, Campa M, Brosch R, Esin S.

Mol Microbiol. 2012 Mar;83(6):1195-209. doi: 10.1111/j.1365-2958.2012.08001.x. Epub 2012 Feb 20.

29.

Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death.

Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, Enninga J.

PLoS Pathog. 2012 Feb;8(2):e1002507. doi: 10.1371/journal.ppat.1002507. Epub 2012 Feb 2.

30.

Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Stanek O, Linhartova I, Majlessi L, Leclerc C, Sebo P.

Mol Biotechnol. 2012 Jul;51(3):221-32. doi: 10.1007/s12033-011-9459-6.

PMID:
22006508
31.

The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells.

Olivier A, Sainz-Perez A, Dong H, Sparwasser T, Majlessi L, Leclerc C.

Eur J Immunol. 2011 Aug;41(8):2303-13. doi: 10.1002/eji.201041387. Epub 2011 Jun 6.

32.

ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis.

Bottai D, Majlessi L, Simeone R, Frigui W, Laurent C, Lenormand P, Chen J, Rosenkrands I, Huerre M, Leclerc C, Cole ST, Brosch R.

J Infect Dis. 2011 Apr 15;203(8):1155-64. doi: 10.1093/infdis/jiq089. Epub 2010 Dec 31.

PMID:
21196469
33.

Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope.

Fayolle C, Davi M, Dong H, Ritzel D, Le Page A, Knipping F, Majlessi L, Ladant D, Leclerc C.

Vaccine. 2010 Oct 4;28(42):6930-41. doi: 10.1016/j.vaccine.2010.07.059. Epub 2010 Aug 20.

PMID:
20728521
34.

Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils.

Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R.

Immunity. 2009 Nov 20;31(5):761-71. doi: 10.1016/j.immuni.2009.09.016. Epub 2009 Nov 12.

35.

Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.

Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A, Castello-Branco L, Leclerc C, Lewis DJ, Marsh PD, Gicquel B, Winter N.

Vaccine. 2009 Jan 1;27(1):28-37. doi: 10.1016/j.vaccine.2008.10.034. Epub 2008 Oct 31.

PMID:
18977269
36.

Regulatory B and T cells in infections.

Majlessi L, Lo-Man R, Leclerc C.

Microbes Infect. 2008 Jul;10(9):1030-5. doi: 10.1016/j.micinf.2008.07.017. Epub 2008 Jul 10. Review.

PMID:
18672084
37.

Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis.

Jaron B, Maranghi E, Leclerc C, Majlessi L.

PLoS One. 2008 Jul 30;3(7):e2833. doi: 10.1371/journal.pone.0002833.

38.

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.

Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P, Garnier T, Gicquel B, Martin C, Leclerc C, Cole ST, Brosch R.

PLoS Pathog. 2008 Feb 8;4(2):e33. doi: 10.1371/journal.ppat.0040033.

39.

Immobilized cytokines as biomaterials for manufacturing immune cell based vaccines.

Leclerc C, Brose C, Nouzé C, Leonard F, Majlessi L, Becker S, von Briesen H, Lo-Man R.

J Biomed Mater Res A. 2008 Sep 15;86(4):1033-40.

PMID:
18067172
40.

Inhibition of phagosome maturation by mycobacteria does not interfere with presentation of mycobacterial antigens by MHC molecules.

Majlessi L, Combaluzier B, Albrecht I, Garcia JE, Nouze C, Pieters J, Leclerc C.

J Immunol. 2007 Aug 1;179(3):1825-33. Erratum in: J Immunol. 2007 Oct 15;179(8):5604.

41.

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C, Brodin P, Sebo P, Leclerc C.

Infect Immun. 2006 Jun;74(6):3396-407.

42.

Processing of the bovine spongiform encephalopathy-specific prion protein by dendritic cells.

Rybner-Barnier C, Jacquemot C, Cuche C, Doré G, Majlessi L, Gabellec MM, Moris A, Schwartz O, Di Santo J, Cumano A, Leclerc C, Lazarini F.

J Virol. 2006 May;80(10):4656-63.

43.

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Majlessi L, Simsova M, Jarvis Z, Brodin P, Rojas MJ, Bauche C, Nouzé C, Ladant D, Cole ST, Sebo P, Leclerc C.

Infect Immun. 2006 Apr;74(4):2128-37.

44.

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.

Brodin P, Majlessi L, Marsollier L, de Jonge MI, Bottai D, Demangel C, Hinds J, Neyrolles O, Butcher PD, Leclerc C, Cole ST, Brosch R.

Infect Immun. 2006 Jan;74(1):88-98.

45.
46.

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.

Majlessi L, Brodin P, Brosch R, Rojas MJ, Khun H, Huerre M, Cole ST, Leclerc C.

J Immunol. 2005 Mar 15;174(6):3570-9.

47.

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.

Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S, Williams A, Leclerc C, Cole ST.

J Infect Dis. 2004 Jul 1;190(1):115-22. Epub 2004 Jun 4.

PMID:
15195250
48.
50.

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST.

Nat Med. 2003 May;9(5):533-9. Epub 2003 Apr 14.

PMID:
12692540

Supplemental Content

Loading ...
Support Center